Huvepharma Signs Agreement to Acquire Euroapi Italy

The Bulgarian pharmaceutical company Huvepharma EOOD has signed an agreement to acquire 100% of the capital of Euroapi Italy S.r.l., a leading Italian manufacturer of pharmaceutical ingredients. The transaction also includes the production facility in Brindisi, Italy, which has a rich industrial heritage in the field of precision fermentation dating back to 1966.

The agreement was signed on July 29, 2026, subject to the fulfillment of all customary conditions for closing the transaction, including obtaining approval for the foreign investment from the local competent authority (Golden Power clearance) and others.

There is excellent synergy between Huvepharma’s modern biotechnology profile and the extensive experience and expertise of the employees at the Brindisi plant,” said Huvepharma CEO Kiril Domuschiev.

“Huvepharma intends to fully leverage these advantages by developing and bringing innovative products and dosage forms to market. We remain focused on the development, production, and marketing of products for veterinary and human medicine, as well as nutraceuticals, and this acquisition is further proof of our long-term commitment to our customers,” he added.

All of the Bulgarian company’s products are manufactured at facilities owned by companies within its group. This ensures full control over production processes and guarantees the highest quality standards. Furthermore, full control over production allows the Huvepharma Group to be flexible and adaptive, enabling it to promptly improve its products in line with changing customer needs.

With this acquisition, the company’s fermentation capacity will increase by 25%, reaching a total capacity of over 12,000 cubic meters.

This further solidifies its position as a European leader in the biotechnology industry and creates opportunities for further expansion of its global business.

The deal once again confirms that Huvepharma’s customers can trust in the company’s long-term, sustainable, and reliable business model for manufacturing its products, the company states.

Translated with DeepL.